WASHINGTON (dpa-AFX) - Biotechnology company Inovio Pharmaceuticals Inc. (INO) announced Thursday positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.
In the first cohort of 21 participants, INO-3107 showed a statistically significant improvement in the clinical endpoint of the number of surgical interventions needed to control papilloma growth.
INO-3107 was also observed to be well-tolerated and immunogenic in the trial. INO-3107 received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) in July 2020.
INO-3107 was evaluated in a Phase 1/2 open-label, multicenter trial to assess its safety, tolerability, immunogenicity, and efficacy in 32 participants with HPV 6 and/or HPV 11-associated RRP.
Results from the second cohort of 11 patients are expected in the first half of 2023.
For More Such Health News, visit rttnews.com
Copyright(c) 2022 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2022 AFX News
